Notwithstanding that the U.S. Food and Drug Administration (FDA) has twice designated psilocybin a Breakthrough Therapy—first for treatment-resistant depression and then for major depressive disorder, the U.S. Drug Enforcement Administration (DEA) has steadfastly refused to even initiate the process for rescheduling the drug. In early 2021, Dr. Sunil Aggarwal and Advanced Integrative Medical Science Institute, PLLC asked the DEA how he might obtain psilocybin for therapeutic use under Right to Try laws. In response, DEA said it had no authority to permit such uses because psilocybin is a schedule I drug permitted for research use only.

This program will explore the potential therapeutic role of Psilocybin, and the paths available to meaningful scientific review of its use.

Speakers:

David N. Hoffman, J.D., Assistant Professor of Bioethics, Columbia University

Steven P. Field, MD, Clinical Assistant Professor, Department of Medicine at NYU Grossman School of Medicine; Medical Ethics Consultant, NYU Langone Medical Center

Linda Brooks Uchal, Research Pharmacist

For further information please contact Athina Fontenot, af3018@columbia.edu.

For additional information about program offerings at Columbia University’s School of Professional Studies, please contact an Admissions Counselor at 212-854-9666 or inquire@sps.columbia.edu.